share_log

德琪醫藥-B：截至2024年1月31日止月份之股份發行人的證券變動月報表

ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

香港交易所 ·  Feb 1 03:25
Summary by Moomoo AI
德琪醫藥有限公司於2024年2月1日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年1月31日的公司股份變動情況。報告顯示，公司法定/註冊股本結存維持在2,000,000,000股，面值0.0001美元，總額200,000美元，本月無增減變動。此外，公司股份期權計劃下，2019股權激勵計劃及2020股權激勵計劃分別註銷了313,700股和311,600股股份期權。經註銷後，2020股權激勵計劃仍有7,387,912股股份期權可供行使。其他發行股份的協議或安排（包括期權）本月內無新增股份數目。報告由公司主席梅建明博士呈交。
德琪醫藥有限公司於2024年2月1日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年1月31日的公司股份變動情況。報告顯示，公司法定/註冊股本結存維持在2,000,000,000股，面值0.0001美元，總額200,000美元，本月無增減變動。此外，公司股份期權計劃下，2019股權激勵計劃及2020股權激勵計劃分別註銷了313,700股和311,600股股份期權。經註銷後，2020股權激勵計劃仍有7,387,912股股份期權可供行使。其他發行股份的協議或安排（包括期權）本月內無新增股份數目。報告由公司主席梅建明博士呈交。
DEKI PHARMACEUTICALS LIMITED FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON FEBRUARY 1, 2024, REPORTING THE CHANGES IN THE COMPANY'S SHARES AS OF JANUARY 31, 2024. THE REPORT SHOWED THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL REMAINED AT 2,000,000,000 SHARES WITH A FACE VALUE OF $0.0001 FOR A TOTAL OF $200,000, WITH NO INCREASE OR DECREASE THIS MONTH. In addition, 313,700 shares and 311,600 share options were written off under the Company's Stock Option Plan 2019 and Stock Incentive Plan 2020, respectively. After the delisting, the 2020 Equity Incentive Program still has 7,387,912 share options available for exercise. Other agreements or arrangements for issuing shares (including options) have not added the number of shares during this month. The report was presented by the Chairman of the Company, Dr. Mei Jianming.
DEKI PHARMACEUTICALS LIMITED FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON FEBRUARY 1, 2024, REPORTING THE CHANGES IN THE COMPANY'S SHARES AS OF JANUARY 31, 2024. THE REPORT SHOWED THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL REMAINED AT 2,000,000,000 SHARES WITH A FACE VALUE OF $0.0001 FOR A TOTAL OF $200,000, WITH NO INCREASE OR DECREASE THIS MONTH. In addition, 313,700 shares and 311,600 share options were written off under the Company's Stock Option Plan 2019 and Stock Incentive Plan 2020, respectively. After the delisting, the 2020 Equity Incentive Program still has 7,387,912 share options available for exercise. Other agreements or arrangements for issuing shares (including options) have not added the number of shares during this month. The report was presented by the Chairman of the Company, Dr. Mei Jianming.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more